http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022502422-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0406 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate | 2019-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022502422-A |
| titleOfInvention | Pharmaceutical agents for labeling inhibitors of prostate-specific membrane antigen (PSMA), their use as imaging agents, and treatment of PSMA-expressing cancers |
| abstract | In the present invention, the formulas (1) (I) [in the formula, Y 3 is O or S, s, t, u and w are 0 or 1, i is an integer of 1 to 3, and j. Is an integer from 3 to 5, and Z 1 , Z 2 and Z 3 are selected from the group consisting of CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, and -OPO 3 H 2. , R 1 is -CH 3 or H, X is selected from the group consisting of alkylaryls, aryls, alkyl heteroaryls and heteroaryls, and Y 1 and Y 2 are aryls, alkylaryls, cycloalkyls, heterocyclos. Selected from the group consisting of alkyl, heteroaryl and alkyl heteroaryl, A is (Ia), (Ib) and (Ic) (in the formula, R 2 , R 3 , R 4 and R 5 are H, -CH. Selected from the group consisting of 2 -COOH and -CH 2 -C (= O) -NH 2 , or R 2 and R 4 form a-(CH 2 ) n -bridge, where n is 1-3. It is an integer, n is preferably 2, r, v and q are 0 or 1, but when u and w are 0, q and v are 0). (A) u and w are 1 or (B) u is 0, w is 1 and A is from (Ia) or (Ib). Selected or (C) A is not]. The compounds are disclosed for use in the treatment of PSMA-expressing cancers. [Selection diagram] None |
| priorityDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.